Department of Experimental Oncology, Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia.
Institute for Bioinnovation, Biomedical Sciences Research Center "Alexander Fleming", Fleming 34, 166 72 Vari, Greece.
Int J Mol Sci. 2023 Oct 21;24(20):15412. doi: 10.3390/ijms242015412.
Locally advanced rectal cancer (LARC) presents a challenge in identifying molecular markers linked to the response to neoadjuvant chemoradiotherapy (nCRT). This study aimed to utilize a sensitive proteomic method, data-independent mass spectrometry (DIA-MS), to extensively analyze the LARC proteome, seeking individuals with favorable initial responses suitable for a watch-and-wait approach. This research addresses the unmet need to understand the response to treatment, potentially guiding personalized strategies for LARC patients. Post-treatment assessment included MRI scans and proctoscopy. This research involved 97 LARC patients treated with intense chemoradiotherapy, comprising radiation and chemotherapy. Out of 97 LARC included in this study, we selected 20 samples with the most different responses to nCRT for proteome profiling (responders vs. non-responders). This proteomic approach shows extensive proteome coverage in LARC samples. The analysis identified a significant number of proteins compared to a prior study. A total of 915 proteins exhibited differential expression between the two groups, with certain signaling pathways associated with response mechanisms, while top candidates had good predictive potential. Proteins encoded by genes , , , , , and showed high predictive potential of unfavorable treatment outcome, while , , , , , , , , , and were good predictive biomarkers of favorable treatment outcome. The identified proteins and related biological processes provide promising insights that could enhance the management and care of LARC patients.
局部进展期直肠癌(LARC)在识别与新辅助放化疗(nCRT)反应相关的分子标志物方面存在挑战。本研究旨在利用灵敏的蛋白质组学方法——数据非依赖采集质谱(DIA-MS),对 LARC 蛋白质组进行广泛分析,寻找适合观望等待策略的初始反应良好的个体。这项研究旨在满足了解治疗反应的需求,为 LARC 患者提供潜在的个性化治疗策略。治疗后评估包括 MRI 扫描和直肠镜检查。本研究纳入了 97 例接受强化放化疗的 LARC 患者,包括放疗和化疗。在本研究中,我们从 97 例 LARC 患者中选择了 20 例对 nCRT 反应最不同的样本进行蛋白质组谱分析(应答者与无应答者)。这种蛋白质组学方法在 LARC 样本中显示出广泛的蛋白质组覆盖。与之前的研究相比,该分析确定了大量的蛋白质。两组之间共有 915 种蛋白质表达差异,某些信号通路与反应机制相关,而候选蛋白具有良好的预测潜力。基因 、 、 、 、 、 和 编码的蛋白质显示出不良治疗结果的高预测潜力,而 、 、 、 、 、 、 、 和 是治疗结果良好的良好预测生物标志物。鉴定的蛋白质和相关生物过程提供了有希望的见解,可增强 LARC 患者的管理和护理。